Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic developmentCash position of $76.3 ...

DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (TIL) (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code ...

Instil Bio is developing a bispecific antibody that strengthens immune responses to solid tumors by simultaneously targeting PD-L1 and VEGF. Instil Bio's lead immunology candidate is still in phase 1 ...

Shares of small biotech Instil Bio TIL have surged more than six times in market value in the past week. The upside came after rival Summit Therapeutics SMMT reported encouraging data from a ...

First Quarter 2024 Financial and Operating Results: As of March 31, 2024, Instil had cash, cash equivalents, marketable securities and long-term investments of $161.5 million, which consisted of $5.5 ...

Summit Therapeutics' trial data drove stocks up by 150% for Summit, 40% for BioNTech and 500% for Instil Bio. Jefferies upgrades Instil Bio with a $52 target, forecasting over 300% upside from the ...

Instil Bio, Inc. announced the clearance of an Investigational New Drug (IND) application for its drug AXN-2510 by the FDA, enabling the company to begin a phase 1 trial before the end of 2025. This ...

ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC ...

If you're an investor looking for stocks that can make dramatic gains in a short amount of time, you may have noticed a small-cap biopharmaceutical company called Instil Bio (NASDAQ: TIL) has been ...